251 related articles for article (PubMed ID: 37010679)
1. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
[TBL] [Abstract][Full Text] [Related]
2. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Lv Z; Luo F; Chu Y
Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
4. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
Moradi V; Omidkhoda A; Ahmadbeigi N
Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
[TBL] [Abstract][Full Text] [Related]
5. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
7. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
Front Immunol; 2021; 12():780145. PubMed ID: 34975869
[TBL] [Abstract][Full Text] [Related]
9. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
Zhao Q; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
[TBL] [Abstract][Full Text] [Related]
10. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
Dhakal B; Chhabra S; Savani BN; Hamadani M
Br J Haematol; 2022 Apr; 197(1):28-40. PubMed ID: 34671973
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
Khurana A; Lin Y
Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
13. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
14. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
[TBL] [Abstract][Full Text] [Related]
16. Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
Torikai H; Cooper LJ
Mol Ther; 2016 Aug; 24(7):1178-86. PubMed ID: 27203439
[TBL] [Abstract][Full Text] [Related]
17. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
[TBL] [Abstract][Full Text] [Related]
18. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?
Watanabe N; Mamonkin M
Cancer J; 2021 Mar-Apr 01; 27(2):176-181. PubMed ID: 33750078
[TBL] [Abstract][Full Text] [Related]
19. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
Davies JK; Singh H; Huls H; Yuk D; Lee DA; Kebriaei P; Champlin RE; Nadler LM; Guinan EC; Cooper LJ
Cancer Res; 2010 May; 70(10):3915-24. PubMed ID: 20424114
[TBL] [Abstract][Full Text] [Related]
20. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]